Streetbeat News

Regulatory

MIRA

Mira Pharmaceuticals shared updates on its preclinical studies for Ketamir-2, expressing optimism that the results will allow the company to file a New Drug Application (NDA) with the FDA by the end of this year.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:04 pm

JAZZ

Jazz Pharmaceuticals has completed the biologics license application for Zanidatamab, aimed at treating previously treated HER2-positive metastatic biliary tract cancer. This marks a significant step in providing a new treatment option for this cancer type.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:00 pm

PRFX

PainReform has reached 50% enrollment in the second part of its Phase III clinical trial of PRF-110 for bunionectomy, as exclusively reported to Benzinga.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:00 pm

ALZN

AZTR

GANX

SILO

Insiders at Alzamend Neuro, Gain Therapeutics, Azitra, and Silo Pharma have recently made significant stock purchases. These transactions come amidst various developments within the companies, such as FDA approvals, executive appointments, financial results, and successful studies, indicating insider confidence in the companies' prospects.

Portfolio Pulse from Avi Kapoor

April 02, 2024 | 11:39 am

JAZZ

RDHL

Jazz Pharmaceuticals has completed a Biologics License Application for Zanidatamab, aimed at treating HER2-Positive Metastatic Biliary Tract Cancer. RedHill Biopharma (RDHL) may also be involved.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 11:31 am

GOEV

PVH

QQQ

SPY

U.S. stocks are poised for a lower open amid concerns over interest rates and economic data. Strong manufacturing data has led to mixed market reactions, with major indices like the DJIA and S&P 500 closing lower. Analysts remain optimistic about the tech sector despite fears of overvaluation. Futures trading indicates a negative start, with SPY and QQQ ETFs down in premarket. Companies like PVH Corp. and Canoo, Inc. reported earnings, leading to significant premarket drops. Health insurance stocks also fell sharply due to concerns over Medicare Advantage program payments.

Portfolio Pulse from Shanthi Rexaline

April 02, 2024 | 11:24 am

CVX

IYE

XLE

Chevron's joint venture with PDVSA, Petroindependencia, has launched a new drilling campaign in Venezuela, following the U.S. easing oil sanctions on Venezuela. This move is part of Chevron's plan to boost its Venezuela crude output by 65,000 barrels per day by the end of the year. The campaign includes drilling 17 wells, with the CMI14 well being the first. Investors can gain exposure to Chevron through SPDR Select Sector Fund – Energy Select Sector (XLE) and iShares U.S. Energy ETF (IYE). Chevron's stock closed higher by 0.85% at $159.08.

Portfolio Pulse from Lekha Gupta

April 02, 2024 | 11:08 am

AUTL

Autolus Therapeutics announced that the European Medicines Agency has accepted its Marketing Authorization Application for Obecabtagene Autoleucel, aimed at treating relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Portfolio Pulse from Charles Gross

April 02, 2024 | 11:07 am

CNC

CVS

ELV

HUM

MOH

UNH

Shares of healthcare providers CNC, CVS, ELV, HUM, MOH, and UNH are trading lower following the CMS's finalization of payment updates for the 2025 Medicare Advantage and Medicare Part D programs.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 11:04 am

BTBT

CVS

HUM

MSTR

PVH

PVH Corp. reported Q4 earnings surpassing analyst estimates with a significant year-over-year increase, but projected a revenue decrease for FY2024, causing its shares to tumble in pre-market trading. Other stocks like Fractyl Health, GCT Semiconductor, Petco Health, Humana, MicroStrategy, Bit Digital, CVS Health, and Lotus Technology also recorded losses in pre-market trading due to various factors including CMS payment updates, Bitcoin's decline, and upcoming financial reports.

Portfolio Pulse from Avi Kapoor

April 02, 2024 | 10:26 am